Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
NCT00253435Phase 2Completed
- Sponsor
- New Advances in Neuroblastoma Therapy
- Start
- Sep 2005
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Iobenguane I-131 in neuroblastoma, sponsored by New Advances in Neuroblastoma Therapy. Primary endpoint: Objective Response Rate. Started Sep 2005; status: completed.
02
Drugs
Iobenguane I-131
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00253435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253435.